Q301--New - QuantiFERON Testing Base + 4
Veterans Affairs · 257-NETWORK CONTRACT OFFICE 17 (36C257)
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 36C25727Q0005 in this department, oldest first.
- Aug 3, 2026Sources SoughtOpen
- Aug 3, 2026 · this noticeSources Sought
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
Statement of Work 1.0 Purpose Request the procurement of supplies and reagent to perform QuantiFERON®- TB Gold Plus testing on the DiaSorin LIAISON XL instrument 2.0 Scope Vendor will provide blood collection tubes, reagents, and controls to perform testing utilizing the DiaSorin LIAISON XL instrument. 3.0 Location The instrument will be located, and testing will be performed in the Client Services and Immunopathology (CSI) section of the Pathology & Laboratory Medicine Service at the VANTHCS, 4500 S. Lancaster Rd, Dallas, TX 75216. 4.0 Performance Test Performance: All tests, procedures, and … (show all)
equipment must perform at manufacturer s specifications. Deviations from the performance specifications shall be corrected by the Contractor. Test performance will be evaluated by and not limited for performance thru peer comparison, quality control and CAP peer evaluation. The vendor shall reimburse VANTHCS for any costs and/or supplies related to tests sent to a referral laboratory when testing is not available through no fault of the facility due to reagent problems, other product issues, instrumentation failure, or other factors. The assessed damages shall be applied to the invoice in the form of a credit or deduction. Safety: The Contractor shall immediately notify VANTHCS of any changes in reagent kit composition, procedure modification, recall notification, or any changes that will affect the performance of the test or procedure according to FDA regulations. 5.0 Period of Performance Cost per Test Purchase Agreement for supplies and reagents will be in effect from December 01, 2026 through November 30, 2027 with four additional option years. Base Period: December 01, 2026 through November 30, 2027 Option 1: December 01, 2027 through November 30, 2028 Option 2: December 01, 2028 through November 30, 2029 Option 3: December 01, 2029 through November 30, 2030 Option 4: December 01, 2030 through November 30, 2031 6.0 Deliverables/Supplies Reagents and supplies will be purchased under the terms of the reagent purchase agreement. The Contractor shall deliver all supplies necessary for test performance at no Government cost. The Contractor shall provide supplies: reagents and consumables for test menu. In the event that requested supplies are on back-order, Contractor is to provide information as to the estimated time of availability. The Contractor shall deliver all invoices for review according to the established contract at the end of each billing cycle. All items not contracted shall be specifically detailed on the invoice including description, quantity acquired, and government cost. Any changes in reagents or equipment modifications shall be immediately disclosed by the Contractor electronically as well as by postal mail with supporting documentation of the change, and detailed guidance for implementation within twenty-four hours of its application. Additional charges incurred by the government to provide the continuity of contracted tests to patients and not limited to out sourcing, transportation, and or any other additional cost shall be covered by the Contractor at no additional charge to the government. Sole Source Justification See form VHAPM Part 813.106 Simplified Acquisition Procedures: Soliciting from a Single Source Attachment 1: Single Source Justification for SAP under the SAT. 8.0 Vendor Security Contract Requirements. This Contractor requires no access to VANTHCS or any VA information system. NO VA DATA OF ANY TYPE SHALL BE TRANSFERRED FROM THE VA. 9. Records Management All records (administrative and program specific) created during the period of the contract belong to VA North Texas Health Care System (VANTHCS) and must be returned to VANTHCS at the end of the contract. Quality Assurance Surveillance Plan (QASP) and its performance are as follows: Standard Task Indicator Acceptable Quality Level Method of Surveillance Incentive Repeat runs are minimal due to reagent or instrument issues. Schedule Successful reporting of results No more than 2 instances of repeat runs due to a single reagent or instrument issue per quarter. Exceptional: 0 Very Good: 1 Satisfactory: 2 Marginal: 3 Unsatisfactory: >3 Troubleshooting records Service records Exercise of Option Period Minimal unsuccessful performance due to instrument or reagent issues. Successful peer group comparison 90% satisfactory performance to peer group. Exceptional: 100% Very Good: 95-99% Satisfactory: 90-94% Marginal: 85-89% Unsatisfactory: <85% CAP survey reports Exercise of Option Period Telephone Support is responsive. Trouble-shooting via phone 95% Issues resolved within 3 calls or elevated to service. Exceptional: 100% Very Good: 98-99% Satisfactory: 95-97% Marginal: 85-89% Unsatisfactory: <85% Troubleshooting records Problem records Service records Exercise of Option Period Invoices are submitted monthly. Cost Control Invoice Accountability 100% Invoices received through OLCS via Austin, Texas Invoice records Exercise of Option Period Invoices are itemized by service or product received. Invoice Verification 80% Invoices contain all necessary information for proper processing. Excellent: 95-100% Very Good: 90-94% Satisfactory: 85-89% Marginal: 80-84% Unsatisfactory: <80% Invoice records Exercise of Option Period Backordered reagents and supplies are minimal. Backorders <5% Backorders per year. Excellent: 0% Very Good: 1-2% Satisfactory: 3-4% Marginal: 5% Unsatisfactory: >5% Order records Invoice records Customer communications Exercise of Option Period Provides timely follow-up for backorders. Management Backorder Notification 90% timely follow up for backorders Exceptional: 100% Very Good: 95-99% Satisfactory: 90-94% Marginal: 85-89% Unsatisfactory: <85% Order records Invoice records Customer communications Exercise of Option Period Contractor will provide proactive notification of changes. Notification of changes in reagent and equipment modifications 100% Proactive notifications. Quality Bulletins Customer Letters Customer Contact Exercise of Option Period Timely recall notification of reagent and supplies. Regulatory Recall Notification 100% Recall notifications within 1 month of issuance. Quality Bulletins Customer Letters Customer Contact Exercise of Option Period Works with customer to resolve complaints. Customer service Substantiated complaints No unresolved substantiated customer complaints per year Order records Invoice records Customer communications Problem records Troubleshooting records Exercise of Option Period Timely follow-up on complaints. Complaint Handling 90% Complaint follow-up within 24 hours of initial complaint or within agreed upon timeframe. Exceptional: 100% Very Good: 95-99% Satisfactory: 90-94% Marginal: 85-89% Unsatisfactory: <85% Order records Invoice records Customer communications Problem records Troubleshooting records Exercise of Option Period
Who won similar work
20 award notices on SAM.gov in the last 24 months. Matched by: Same office (257-NETWORK CONTRACT OFFICE 17 (36C257)), same product/service code (PSC) Q301.
Single-winner award sizes (20): middle half $447K to $4.8M, median $2.0M; range $51K to $17.0M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| QUEST DIAGNOSTICS INCORPORATED · $DGX · $11.6B | 8 | $49.6M | Mar 3, 2026 |
| LABORATORY CORPORATION | 4 | $22.7M | Apr 27, 2026 |
| PROPATH SERVICES, LLC | 1 | $4.0M | Jun 11, 2026 |
| BEXAR COUNTY HOSPITAL DISTRICT SAN ANTONIO 78229 | 1 | $2.6M | Nov 20, 2024 |
| ARUP LABORATORIES INC | 1 | $450K | Mar 19, 2025 |
| VETERANS HEALTHCARE SUPPLY SOLUTIONS, INC | 1 | $438K | May 13, 2026 |
| ABBOTT LABORATORIES INC. · $ABT · $45.1B | 1 | $330K | Dec 19, 2024 |
| UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER OF SAN ANTONIO SAN ANTONIO 78229 | 1 | $275K | Sep 22, 2025 |
| AMBRY GENETICS CORPORATION | 1 | $62K | Feb 26, 2026 |
| ABBOTT RAPID DIAGNOSTICS INFORMATICS, INC | 1 | $51K | Dec 2, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $DGX reported $11.6B revenue (12 months to Jun 30, 2026). The median single-winner award in these 20 past awards, $2.0M, is under 0.1% of that. SEC filing
- $ABT reported $45.1B revenue (12 months to Mar 31, 2026). The median single-winner award in these 20 past awards, $2.0M, is under 0.1% of that. SEC filing
One award's total value against one year of revenue; many awards are paid over several years.
- Jun 11, 2026PROPATH SERVICES, LLC$4.0MQ301--NEW - NTX Combined Reference Lab Testing (Anatomic, Surgical, Genetic) IDIQNo listed company matched (Materiality N/A)
- May 13, 2026VETERANS HEALTHCARE SUPPLY SOLUTIONS, INC$438KQ301--WatchPat One Direct Sleep w/ServiceNo listed company matched (Materiality N/A)
- Apr 27, 2026LABORATORY CORPORATION$17.0MQ301--STX Specialized Reference Lab TestingNo listed company matched (Materiality N/A)
- Mar 29, 2026LABORATORY CORPORATION$815KQ301--South Texas VA Specialized Reference Lab Testing 3 Month OrderNo listed company matched (Materiality N/A)
- Mar 3, 2026QUEST DIAGNOSTICS INCORPORATED$12.4MQ301--Specialized Reference Lab Services BPA South Texas Veterans Healthcare SystemMateriality: 0.11% of $DGX revenue (Low) SEC
- Feb 27, 2026QUEST DIAGNOSTICS INCORPORATED$12.8MQ301--Reference Laboratory Testing Services BPA El Paso Veterans Healthcare SystemMateriality: 0.11% of $DGX revenue (Low) SEC
- Feb 27, 2026QUEST DIAGNOSTICS INCORPORATED$5.5MQ301--New - NTX Reference TestingMateriality: 0.05% of $DGX revenue (Low) SEC
- Feb 26, 2026AMBRY GENETICS CORPORATION$62KQ301--Specialized Genetic Testing ServicesNo listed company matched (Materiality N/A)
- Jan 20, 2026QUEST DIAGNOSTICS INCORPORATED$4.6MQ301--Reference Laboratory Services Central Texas Veterans Healthcare SystemMateriality: 0.04% of $DGX revenue (Low) SEC
- Jan 7, 2026QUEST DIAGNOSTICS INCORPORATED$2.0MWest Texas VA Reference Lab TestingMateriality: 0.02% of $DGX revenue (Low) SEC
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Veterans Affairs, Dept of (VA) since 2024 (5 filings)
- 0 of their lobbyists list a past Veterans Affairs, Dept of (VA) job
- $69K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Veterans' Affairs, Senate Committee on Appropriations, Senate Committee on Veterans' Affairs
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 5 bills named on the past winners' lobbying filings
- 25 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 2 of the past winners are listed companies
- 0 insider buys and 5 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.